← Leaderboards
Peter B Madrid
Sri International
$3,303,382
Attributed
$3,303,382
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2009–13$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$3,303,382 · 3
By mechanism
U01$1,837,524 · 1
R56$1,046,974 · 1
R21$418,884 · 1
Top collaborators
No co-investigators on record.
Most similar at Sri International
Same institution · by research overlap
- Brian J Murphy$2,690,293
- Keith R. Laderoute$4,714,103
- Michal Avital-Shmilovici$370,293
- Xiaohe Liu$979,575
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignBaseLeadIn Vitro ActivityScreening ProcedureAntibioticsToxic EffectPharmaceutical ChemistryOralResistanceCounterscreenLibrariesPathogenPermeabilityCombinatorialMetabolicInhibitor/AntagonistAnalogIn VitroEnzymesBinding (Molecular Function)Binding SitesBiological AvailabilityGrowth
Grant awards (5)
Gyrase B Inhibitors for Mycobacterium Tuberculosis$187,023
R21 · FY2013 · AI · contact PI
Gyrase B Inhibitors for Mycobacterium Tuberculosis$231,861
R21 · FY2012 · AI · contact PI
Development of Benzotriazine Oxides as Therapeutics for Drug Resistant Tuberculos$1,046,974
R56 · FY2010 · AI · contact PI
Dual Action Inhibitors of Gyrase Beta and Histidine Kinases as Broad-Spectrum Ant$982,218
U01 · FY2010 · AI · contact PI
Dual Action Inhibitors of Gyrase Beta and Histidine Kinases as Broad-Spectrum Ant$855,306
U01 · FY2009 · AI · contact PI